Sun Pharma Advanced Research Company Limited (NSE:SPARC)
India
· Delayed Price · Currency is INR | Market Cap | 40.92B |
| Revenue (ttm) | 611.35M |
| Net Income (ttm) | -3.89B |
| Shares Out | 324.52M |
| EPS (ttm) | -11.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,249,886 |
| Average Volume | 3,010,519 |
| Open | 127.00 |
| Previous Close | 126.10 |
| Day's Range | 123.00 - 127.00 |
| 52-Week Range | 109.30 - 472.80 |
| Beta | 0.87 |
| RSI | 39.79 |
| Earnings Date | May 21, 2025 |
About NSE:SPARC
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company’s products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which... [Read more]
Financial Performance
In 2023, NSE:SPARC's revenue was 755.45 million, a decrease of -68.36% compared to the previous year's 2.39 billion. Losses were -3.87 billion, 74.0% more than in 2022.
Financial StatementsNews
SPARC signs binding LOI with UCSF and Tiller Therapeutics for pre-clinical oncology asset
Sun Pharma Advanced Research Company has recently informed exchanges that the company signed a binding Letter of Intent (LOI) with the University of California, San Francisco (UCSF) and Tiller Therape...
Sun Pharma Advanced Research Q2 revenue at Rs 12.86 crore; net loss widens to Rs 107.33 crore
Sun Pharma Advanced Research Company Limited (SPARC) has released its unaudited consolidated financial results for the quarter and half-year ended September 30, 2024, reflecting a challenging period w...